Agenda

SAME INSIGHTFUL CONTENT… NEW 3-DAY VIRTUAL FORMAT…

Note that the content of the Program Agenda below will remain, and be reformatted to accommodate our new 3-day virtual conference platform and schedule. Stay tuned for more details…

MASTERCLASS WORKSHOPS
Tuesday, September 29, 2020
CONFERENCE DAY 1
Wednesday, September 30, 2020
CONFERENCE DAY 2
Thursday, October 1, 2020

Masterclass Registration and Networking Breakfast

Developing a Competitive Activity Framework to Enhance Organizational Competitiveness

Dr. Harshal Kubavat, Head of Strategic Consulting, INOVIS Life Sciences

This workshop session (with breakouts), will give participants first-hand insights from a combined 30+ years of experience in delivering strategic and tactical workshop-style solutions, using an optimal blend of established CI frameworks alongside INOVIS’ in-house proprietary methodologies.

Key to this session will be addressing business needs across the lifecycle, whereby participants will:
• Develop an in-depth understanding of how a diverse range of facilitated activities (Rapid Immersion, Threat Assessment and Competitor Simulations) can help deliver strategic and competitive insights within an organization
• Appreciate the importance of leveraging the outcomes of workshops to inform and direct decision making
• Receive hands-on opportunities to apply learnings to a pharma case-study in a learning environment

Using business case studies, real-life experiences and validated theory, the INOVIS team will equip you with a number of go-to techniques that can be rapidly integrated into ongoing CI Practice, whether you’re a seasoned CI professional veteran, or newer to the field.

Masterclass Networking Lunch

Best Practices to Create/ Write Effective and Impactful CI Reports and Presentations

Dave Alderman, President Molekule Consulting
Dr. Daniel Pascheles, CEO, Molekule Consulting

An “art” and “science” exists when considering clear, concise and actionable competitive strategy report writing in the biopharmaceutical space.

Many biopharma CI reports disseminated by the Agency are overly verbose, high-level and lack the substantive actionability required for internal usage – facilitating a seamless cascade to management & leadership.

Today’s workshop will translate classical stylistic business writing techniques including those of Strunk and White to the 21st-century biopharmaceutical CI and Strategy world.

In this workshop, we will facilitate two (2) breakouts during which “raw intelligence learnings” will be synthesized and translated into actionable CI deliverables using PowerPoint writing skills and infographic design techniques.

This Workshop is facilitated by David Alderman, President of Molekule Consulting, a global competitive intelligence and strategy consultancy dedicated to the life sciences and biopharmaceutical verticals. David has deep experience from early-development to late-lifecycle management and beyond within biopharma across the competitive landscape among myriad therapy areas, players and subject matters. David is a Subject Matter Expert on the biopharmaceutical vertical; with a particular focus on competition within branded biopharma, small molecule generics and biosimilars.

Masterclasses Conclude

Depending upon the number of registrants, we may be running the same masterclass concurrently in different meeting rooms to maintain social distancing, or we’ll run it consecutively so it’s run twice at different times, i.e. the first masterclass will be from 9:00AM – 11:00AM then again from 11:00AM – 1:00PM. The second masterclass would run from 1:30PM – 3:30PM then again from 3:30PM – 5:30PM.

Registration & Networking Breakfast in Exhibition Hall and Supplier Hosted Breakfast in Various Meeting Rooms

Chairpersons’ Opening Remarks

Mary Ann Sarao, Director, Global Competitive Intelligence, Bayer Consumer Health
Diana Gowe, Director, Competitive Intelligence Excellence, Johnson & Johnson

Presented by Bayer and Johnson & Johnson

Keynote: Innovation Trends in the New Decade

Nishta Rao, Managing Director, BioLabs@NYULangone

Presented by BioLabs@NYULangone

Keynote: CI as Usual in an Unusual Environment – Lessons Learned from the COVID-19 Pandemic

Dr. Daniel Pascheles, CEO, Molekule Consulting

Daniel will share with the audience his learning and experiences in building and successfully leading CI teams over a time span of more than 20 years in the industry.

Topics we will cover:
• What must be in place to seamlessly transition you CI function from an environment of “business as usual” to “business as usual in an unusual environment”?
• What skills and tools need to be in place to adapt such a dramatic change of doing business?
• What processes work and what pitfalls to avoid?

The audience can expect to be able to participate actively in the “conversation” and contribute to the program

Presented by Molekule Consulting

Refresh and Connect in Exhibition Hall and Various Meeting Rooms Hosted by Suppliers with Refreshments

Keynote: Executive Level Discussions: Impact to CI Teams

A panel of CI Leaders from the following companies:

Presented by Presented by Abbott Laboratories, Bayer Consumer Health, BioMarin, Boehringer Ingelheim, Eli Lilly and Company, Johnson & Johnson, Merck, and Novartis Institutes for BioMedical Research

STAGGERED SCHEDULE FOR LUNCHEON AND ROUND TABLES

GROUP A


11:50AM - 12:45PM Networking Luncheon A
11:50AM – 12:45PM "Ask the Experts" Breakout Groups
Plus the option of luncheons in smaller meeting rooms
hosted by suppliers

GROUP B


12:50PM – 1:50PM "Ask the Experts" Breakout Groups
12:50PM – 1:50PM Networking Luncheon B
Plus the option of luncheons in smaller meeting rooms
hosted by suppliers

 

“Ask the Experts” Interactive Breakout Groups

Explore and capture the power of participants’ insights and experiences of these topics in this fun and informal environment.
BREAKOUT 1
How we Practice CI: Integrating Primary and Secondary Insights and Effectively Communicating Impact to Program Decisions

Presented by Seattle Genetics

BREAKOUT 2
The Tactical Guidebook to Impactful CI Workshops

Presented by Ionis Pharmaceuticals

BREAKOUT 3
Importance of CI for Emerging to Mid-size Pharma

Presented by Amneal Pharmaceuticals

BREAKOUT 4
TBA

Presented by Course5

BREAKOUT 5
Personal Development and Mentoring Relationships

Presented by Merck

BREAKOUT 6
Manufacturing Intelligence

Presented by ThermoFisher Scientific

BREAKOUT 7
“Global” vs “Local” CI

Presented by Sanofi (invited)

BREAKOUT 8
TBA

Presented by AstraZeneca (invited)

Idea Labs: Gain New Perspectives

SESSION ONE

Lessons from Inside Novartis, Roche, and Atacana - 5 Questions You Need to Ask to Maximize Your Success and Significantly Increase the Value of Your Competitive Intelligence

Many CI professionals fail to understand that the perceived value of their CI work is the basis for their career success.

Still, others fail to realize that they must translate the importance of their insights into long-term gains for the stakeholders in the stakeholders’ perception.

One of pharma’s most successful CI professionals reveals 5 questions you must ask at the beginning of each project to ensure:

1. A dramatic return on investment for your CI efforts
2. Be recognized for the impact you are creating in your organization
3. Increase your resources and get your next promotion

In this presentation, Salvador Carlucci clearly demonstrates how CI professionals can educate their stakeholders on how to determine the real value of competitive intelligence and how to capture that value to propel their career. Filled with inspirational stories and practical advice, make sure not to miss this presentation.

Presented by Atacana Group

SESSION TWO

Driving Business Success with Powerful Primary CI

• What is primary CI’s role in shaping long term strategy?

• When and how should you adapt your CI plan to changing markets?
• What we can learn from tangible examples of primary CI’s impact on a business’s success?

Presented by Deallus

SESSION THREE

Using Machine Learning to Enrich Pharma CI and Social Media Planning

The emergence of practical, AI-based machine learning technology is a boon to pharmaceutical industry researchers and marketers.

For CI professionals, a machine learning-enabled research portal now can automatically mine and synthesize insights from all manner of documents — including industry news, scientific conference abstracts, primary and secondary market research, and even social media (screening out posts that may contain references to “adverse events”) — saving them valuable time, and zeroing in on the most relevant information needed to inform critical business decisions.

For social media planners, machine learning today can conduct a semantic analysis of keywords in social posts about a topic of interest, which yields clear guidance as to which terms have actual business relevance and are therefore worth investing in. (Consider that, on Twitter, the terms that most frequently co-occur with #cancer all have to do with astrology — #Scorpio, #Pisces, #Ascendant — which is not at all helpful to a pharmaceutical company marketing an anti-cancer drug.)

Attendees at this session will learn:

> the four essential ingredients needed to put machine learning to practical use in pharma CI
> best practices to ensure that your organization can safely use social media for research and marketing
> how one leading pharma company is employing machine learning in its CI efforts today

Presented by Northern Light

Think Tanks: Learning Environment

SESSION ONE

The Forgotten Pharma CI Corner; Cost of Goods (COGs) Intelligence

With the CAR-T and gene therapy revolutions, biosimilar/biobetter challenges to long established biologic innovators and a surge in vaccine innovation, manufacturing and supply chain intelligence is rising in its importance. In 2014 Dig Worldwide developed and introduced COGIntel, a quick, robust and cost effective COGs benchmarking solution.

Technical Cost Modelling (TCM), a method developed at MIT in the 1980’s has long been the gold standard in benchmarking cost-of-goods sold which is time and resource intensive with a limited shelf-life. Although not as precise as TCM, Dig Worldwide’s bespoke COGIntel method allows rapid and cost effective COG benchmarking analysis that provides “good enough” competitive intelligence for strategic decision making. Performance gaps and areas of advantage or disadvantage become visible verses forgotten.

An illustrative CAR-T case study will form an integral part of the talk to help illustrate Dig Worldwide’s methodology.

Presented by Dig Worldwide

SESSION TWO

Top 10 Challenges in CI – How to Face them Head-On

There is need for a “shake-up” in competitive intelligence.

Old-school and business-as-usual methodologies and deliverables will not cut it in an ever-changing business and technological environment that demands greater efficiencies in collection and analysis, and greater demands on ROI effectiveness of CI deliverables. As the American-Canadian writer William Gibson once said, “The future is already here – it’s just not very evenly distributed.” Prescient has surveyed CI stakeholders and has captured a list of the top challenges faced by CI teams. We will discuss the industry “norms” and the advent of budding new and futuristic solutions that will shake up the way we think of CI.

Presented by Prescient Healthcare Group

SESSION THREE

Planning for new Pharmaceutical Markets

Recent developments in the holistic pharmaceuticals market presage significant changes in the overall power dynamics.

Acquisitions such as the CVS/Aetna merger and the Walgreens/Express Scripts group purchasing alliance are indications of new trends in the market. These trends have the potential to significantly change how decisions are made in the market. This session will present a set of future scenarios that depict the market based on extension of the trends. Using interactive tools, participants will model out strategies that pharmaceutical companies will need to implement to thrive in the environment.

Key Take-aways:
1. New thinking about how the traditional pharmaceutical market will change by 2030
2. Expanded awareness of potential impacts from alliances between health insurance carriers, pharmacies, and pharmacy benefits managers
3. Exploration into ways the government can intervene in the market based on different scenarios
4. Broad strategic options for pharmaceutical companies

Presented by Fletcher/CSI

SESSION FOUR

Predicting Genetic Timelines - FDA

Presented by Lifescience Dynamics

Refuel & Rejuvenate in Exhibition Hall, and Various Meeting Rooms Hosted by Suppliers with Refreshments

Leadership Insight: Case Studies

SESSION ONE

New Product Planning: What do you Need to Know When?

Competitive Intelligence needs change by stage of product development.

Early in life information on disease area and other new products as well as standard of care is crucial. As you enter into the 5 years preceding launch and Phase III needs become specific: registrational benchmarks, competition in terms of market share, trial and launch strategy.

Presented by Ipsen Biopharmaceuticals

SESSION TWO

Using Internal Social Media Tools to Enhance Conference Coverage

Presented by REGENXBIO (invited)

SESSION THREE

Collecting Primary CI Best Practices Post COVID

Presented by Biogen

SESSION FOUR

TBA

Presented by Eli Lilly and Company

Engagement: High Level Debate and Discussion

SESSION ONE

Panel Discussion: Role of CI in BD Due Diligence

Presented by Amicus Therapeutics, Amneal Pharmaceuticals, Blueprint Medicines, GlaxoSmithKline, and Spectrum Pharmaceuticals

SESSION TWO

Panel Discussion: Insights into New Product Planning and Decision Making

Presented by AbbVie (invited), Bayer Healthcare, Novartis Oncology, Taiho Oncology, and Takeda Pharmaceuticals

SESSION THREE

Panel Discussion: How CI Impacts Decisions from a Quantitative Perspective, Driven by Primary CI

Presented by
Atara Biotherapeutics, Daiichi Sankyo, and Roche Diagnostics

Cocktail Reception, Networking, and TBD Social Activities

REGISTRATION & NETWORKING BREAKFAST IN EXHIBITION HALL AND SUPPLIER HOSTED BREAKFAST IN VARIOUS MEETING ROOMS

Chairpersons’ Opening Remarks

Mary Ann Sarao, Director, Global Competitive Intelligence, Bayer Consumer Health
Diana Gowe, Director, Competitive Intelligence Excellence, Johnson & Johnson

Presented by Bayer and Johnson & Johnson

Keynote: Systems of Thinking and Influencing your Stakeholders

Dr. Alfred Reszka, Chief Business Officer, Lifescience Dynamics

Presented by Lifescience Dynamics

Keynote: Late Life Cycle Management (LLCM): The Strategic Value of Generic & Biosimilar CI In Life Sciences

Dr. Baljit Singh, Managing Director and Partner, INOVIS, Pharmaceuticals and Life Sciences Division (formerly Director, Integrated Insights, Novartis)

This session will provide insights and highlight best practices to enable LLCM value and asset maximization by leveraging a number of tools unique to CI professionals.

Specifically this presentation will enable you to:
• Advance your understanding of core Gx/biosimilar market dynamics and corresponding CI solutions
• Set up a best-in-industry Gx/biosimilar regulatory intelligence (RI) and CI tracking program
• Understand Gx / biosimilar product development and entry strategies

Presented by INOVIS

REFRESH AND CONNECT IN EXHIBITION HALL AND VARIOUS MEETING ROOMS HOSTED BY SUPPLIERS WITH REFRESHMENTS

Case Histories: Sharing Experiences and Expertise

SESSION ONE

Insight on Clinical Trials COVID-19 and Cancer

Presented by Janssen

SESSION TWO

Federal Policy Changes & COVID Stimulus Packages: Where Did Your Disease Go?

• Overview of policy changes that have had the most influence on site of care

• How has it changed care management? Some examples
• Who are the new/emerging voices that should be part of your new intelligence plan?

Presented by Summit Therapeutics

SESSION THREE

TBA

Presented by Momenta Pharmaceuticals

Idea Labs: Gain New Perspectives

SESSION ONE

Operationalising Competitive Insights in a Virtual Environment

Presented by Osprey Health Consulting

SESSION TWO

10 Lessons from a CI Life

After 17 years at Pfizer and 25 years as a CI professional in both industry and consultancy, Marjorie Norman has seen a lot of changes.

However, some basic truths still hold strong. This session will address Marjorie’s experience – the good, the bad and the ugly – in developing and maintaining a best-in-class CI program.

Presented by Cambridge Healthcare Research

SESSION THREE

Key Issues in Managed Care and Specialty Pharmacy: Impact on the Industry

Presented by Healthcare Intelligence and Analytics

Best Practices and Insights

SESSION ONE

Launching a Product in Challenging Conditions

Presented by SK Life Science

SESSION TWO

The Power of Activating/Leveraging Internal Company Sources & Networks for Intelligence Gathering

Presented by Pfizer

SESSION THREE

Right Sizing Your CI Efforts

What can you do when your client wants to know everything and your resources (time, budget, headcount, secondary services) are thin.

If you have an abundance of resources, is deep analytics the right answer? Ms. Saraos has led large CI programs at Roche/Genentech, consulted with various small non-commercialized biotechs, and is now at medium-sized biopharma, Jazz Pharmaceuticals. She will share her perspective on different ways to think about right sizing CI efforts that build trust and confidence with key stakeholders. Ms. Saraos will share types of bad behavior and lessons learned on how to get to a healthy CI place.

Presented by Jazz Pharmaceuticals

STAGGERED SCHEDULE FOR LUNCHEON AND ROUND TABLES

GROUP A


12:50PM - 1:50PM Networking Luncheon A
1:55PM – 2:55PM "Ask the Experts" Breakout Groups
Plus the option of luncheons in smaller meeting rooms
hosted by suppliers

GROUP B


12:50PM - 1:50PM "Ask the Experts" Breakout Groups
1:55PM – 2:55PM Networking Luncheon B
Plus the option of luncheons in smaller meeting rooms
hosted by suppliers

 

“Ask the Experts” Interactive Breakout Groups

Explore and capture the power of participants’ insights and experiences of these topics in this fun and informal environment.
BREAKOUT 1
How we Practice CI: Integrating Primary and Secondary Insights and Effectively Communicating Impact to Program Decisions

Presented by Seattle Genetics

BREAKOUT 2
The Tactical Guidebook to Impactful CI Workshops

Presented by Ionis Pharmaceuticals

BREAKOUT 3
Importance of CI for Emerging to Mid-size Pharma

Presented by Amneal Pharmaceuticals

BREAKOUT 4
TBA

Presented by Course5

BREAKOUT 5
Personal Development and Mentoring Relationships

Presented by Merck

BREAKOUT 6
Manufacturing Intelligence

Presented by ThermoFisher Scientific

BREAKOUT 7
“Global” vs “Local” CI

Presented by Sanofi (invited)

BREAKOUT 8
TBA

Presented by AstraZeneca (invited)

Announcement of Raffle Prize Winners

Keynote: TBA

Review and Discussion of the Most Controversial and Important Topics over the Two Days

A panel of CI Leaders from the following companies:

Presented by Presented by Abbott Laboratories, Bayer Consumer Health, BioMarin, Boehringer Ingelheim, Eli Lilly and Company, Johnson & Johnson, Merck, and Novartis Institutes for BioMedical Research

Conference Concludes

“COVID-conscious” Guidelines Distributed in Detail On-site but Includes:

• Use of masks required: Please bring your own if preferred, but masks and hand sanitizer will also be provided.
• Greetings should be socially distanced: no handshakes, hugs, or kisses, etc.
• Meeting space will accommodate more spacing between attendees.
• The hotel experience will be entirely revamped with specific cleaning protocols.

error: Content is protected !!